HCQ-SAFE 研究:共享决策工具改善 SLE 患者羟氯喹依从性与结局的实用性试验
本研究开发并评估了基于图表的共享决策工具 HCQ-SAFE,用于系统性红斑狼疮(SLE)就诊时改善羟氯喹(HCQ)决策与依从性。在 200 例成人 SLE 患者中,干预可行且耗时约 5 分钟;不依从者调整后 HCQ 依从性提高 47%(95%CI 38-57),残余决策冲突从 43% 降至 1%。
要点
- HCQ-SAFE 共享决策工具在护士、药师和医师中均高度可行,平均耗时 5 分钟。
- 不依从患者干预后调整依从性提高 47%(95%CI 38-57)。
- 残余决策冲突(DCS≥25)从基线 43% 降至干预后 1%。
核心结论
- HCQ-SAFE 是可行的共享决策干预,有潜力改善 SLE 患者 HCQ 依从性并减少决策冲突。
研究设计与样本
- 在两家医疗系统八家诊所招募 200 例正在服用 HCQ 的成人 SLE 患者。
- HCQ-SAFE 以英文和西班牙文开发,经 30 名患者和临床顾问迭代过程形成。
- 采用配对 t 检验和调整线性回归比较干预前后依从性(PDC)与决策冲突(DCS)变化。
主要发现
- 基线时 62% 患者 HCQ 依从(PDC≥80%),43% 存在残余决策冲突(DCS≥25)。
- 护士(21%)、药师(29%)和医师(50%)报告高可行性(均值 8.5),完成干预需 5 分钟(IQR 5-7)。
- 不依从者调整后 HCQ 依从性提高 47%(95%CI 38-57)。
- 干预后仅 1% 患者报告残余决策冲突,DCS 评分平均变化 35 分(95%CI -30 至 -39)。
- 结果在不同语言、教育水平和临床角色间均显著(P < 0.0001)。
关键数值与推荐
- 依从性定义:PDC≥80%。
- 残余决策冲突定义:DCS≥25。
- 可行性评分均值 8.5,干预耗时中位数 5 分钟(IQR 5-7)。
- 不依从者调整后依从性提高 47%(95%CI 38-57)。
- DCS 评分平均变化 35 分(95%CI -30 至 -39),P < 0.0001。
临床怎么用
- 可在 SLE 就诊中由护士、药师或医师使用 HCQ-SAFE 图表工具进行共享决策,约 5 分钟完成。
- 该工具可能帮助识别并减少患者对 HCQ 的决策冲突,从而改善依从性。
局限性
- 原文未报告对照组或随机化设计,结果为干预前后比较。
- 样本来自两家医疗系统八家诊所,外推性需进一步验证。
- 原文未报告长期临床结局(如疾病活动度、复发)数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hydroxychloroquine (HCQ) nonadherence in systemic lupus erythematosus (SLE) stemming from decision complexities can be improved with shared decision-making (SDM) tools clarifying benefits and harms. This study aimed to develop and evaluate HCQ-SAFE, a pictogram-based SDM tool during SLE visits. METHODS: HCQ-SAFE was developed in English and Spanish using an iterative process with 30 patient and clinician advisers. We recruited 200 adults with SLE on HCQ across eight clinics in two health systems. Implementation outcome metrics, including mean feasibility ratings and time to complete intervention, were collected. We examined the mean change in adherence using proportion of days covered (PDC) data and Decisional Conflict Scale (DCS) scores post-HCQ-SAFE intervention compared with baseline using paired t-test and adjusted linear regression. RESULTS: Among 200 participants, 90% were female, 51% were White, 8% spoke Spanish, and 50% reported high school education or less. At baseline, 62% were adherent to HCQ (PDC ≥80%), and 43% reported residual decisional conflicts (DCS ≥25). Nurses (21%), pharmacists (29%), and physicians (50%) reported high feasibility (mean = 8.5) and required five minutes (interquartile range [IQR] 5-7) to complete the intervention during a visit. Among HCQ nonadherers, adjusted HCQ adherence improved by 47% (95% confidence interval [CI] 38-57). Post-intervention, only 1% of patients reported residual decisional conflicts, and mean change in DCS scores was 35 points (95% CI -30 to -39) after intervention. Findings were significant across language, education level, and clinician role (P < 0.0001). CONCLUSION: HCQ-SAFE is a feasible SDM intervention with the potential to improve adherence and reduce decisional conflicts.
引用
- Packee C, Patel JJ, Kent J, et al. A Pragmatic Trial of a Shared Decision-Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ-SAFE Study. Arthritis Rheumatol. 2026. PMID: 42148466. doi:10.1002/art.70223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。